Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection |
| |
Authors: | Norma Olivares-Zavaleta William Whitmire Donald Gardner Harlan D. Caldwell |
| |
Affiliation: | 1. Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, 903 S. 4th Street, Hamilton, MT 59840, USA;2. Veterinary Pathology Section, Rocky Mountain Laboratories NIAID, NIH, 903 S. 4th Street, Hamilton, MT 59840, USA |
| |
Abstract: | Here we report on the safety, immunogenicity, and vaccine efficacy of the naturally occurring plasmid-free attenuated Chlamydia trachomatis L2-25667R (L2R) strain in a murine infection model. Intravaginal immunization induced both chlamydial specific serum antibody and systemic CD4+ Th1 biased immune responses but failed to induce local IgA antibodies. Immunization induced no pathological changes in the urogenital tract. Protective immunity was evaluated by vaginal challenge with a natural occurring non-attenuated plasmid positive C. trachomatis urogenital strain (serovar D). Vaccinated mice were not protected from colonization/infection but exhibited a reduction in infectious burden at early time periods (1–2 weeks) post-challenge. Partial protective immunity did not protect against inflammatory disease. Thus, intravaginal vaccination with the live-attenuated L2R stain is safe, induces a systemic antibody and CD4+ Th1 biased immune response, but its protective efficacy is limited to reducing chlamydial burden at early time periods post-infection. |
| |
Keywords: | Live-attenuated Chlamydia vaccine Immunogenicity Safety Protective efficacy Urogenital infection model |
本文献已被 ScienceDirect 等数据库收录! |
|